Nuvectis Pharma (NVCT) Other financing activities (2021 - 2025)

Nuvectis Pharma has disclosed Other financing activities across 5 years of filings, most recently posting $82000.0 for Q4 2025.

• Other financing activities for Q4 2025 came in at $82000.0, down 33.87% year-over-year; the trailing twelve-month figure through Dec 2025 was $548000.0 (up 43.46% YoY), and the FY2025 annual result was $548000.0, up 43.46% from the prior year.
• Other financing activities came in at $82000.0 for Q4 2025 at Nuvectis Pharma, up from -$1.1 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $1.6 million in Q2 2021 to a low of -$1.2 million in Q2 2023.
• The 5-year median for Other financing activities is $130000.0 (2021), against an average of $177333.3.
• Across the five-year window, Other financing activities surged 875.0% in 2024 and plunged 2272.0% in 2025, its largest moves.
• Nuvectis Pharma's Other financing activities stood at $136000.0 in 2021, then plunged by 720.59% to -$844000.0 in 2022, then surged by 98.1% to -$16000.0 in 2023, then soared by 875.0% to $124000.0 in 2024, then plunged by 33.87% to $82000.0 in 2025.
• The last three Other financing activities figures came in at $82000.0 (Q4 2025), -$1.1 million (Q3 2025), and $300000.0 (Q2 2025), per Business Quant data.